Laser/drug treatment for AMD (advanced micro devices) lasts two years:
This article was originally published in Clinica
Initial results from a Phase III trial of Visudyne phototherapy for treating age-related macular degeneration (AMD) have shown that its benefits are sustained over a two-year period. The treatment, in which the drug is injected into the arm and non-thermal laser light is shined on the eye, is under development by CIBA Vision and Vancouver, Canada-based QLT PhotoTherapeutics. It is in a Phase III trial for wet AMD and a Phase IIIb trial for choroidal neovascularisation.
You may also be interested in...
The European Commission has unexpectedly concluded that CBD should not be considered as drug opening up the path to regulated EU market for the cannabinoid as a novel food.
As Apotex names its new US president and CEO, Akorn puts together a fresh board of directors following bankruptcy proceedings. Stada has made new appointments in Germany, while Siegfried makes significant changes in its leadership roles.
A WHO recommendation to explicitly exempt low-THC CBD from international narcotics controls has been emphatically rejected by UN member states. The CBD industry had hoped for a positive outcome to remove regulatory pressure on product manufacturers in Europe and around the world.